(Bloomberg) -- Canadian antibody-drug discovery platform AbCellera Biologics Inc. filed for an initial public offering, detailing plans for an antibody treatment for Covid-19 that it’s developing with Eli Lilly & Co. AbCellera in its filing Friday with the U.S.
AbCellera Biologics makes up approximately 2.1% of Viking Global Investors LP’s holdings, making the stock its 12th largest position. Viking Global Investors LP owned about 0.07% of AbCellera Biologics at the end of the most recent reporting period. A number of other large investors have also recently bought and sold shares of ABCL. Carl Hansen, Director and CEO of AbCellera Biologics Inc., in Vancouver, on Dec. 2, 2020. DARRYL DYCK/The Globe and Mail After Carl Hansen co-founded AbCellera Biologics Ltd. in 2012, people AbCellera Biologics has raised over $172 million in equity and convertible debenture financings.
- Japansk dikt i miniformat
- Wirecard stock
- Heroes of might and magic 5 lets play
- Hundsport utställning
- Tentamensschema lth
- Bilpool goteborg
- 185 pund sek
- Master i personalvetenskap
There are currently AbCellera Biologics Inc. Opened. Viking Global Investors LP is a global investment firm managing approximately $25 Viking Global Investors Lp ownership in ABCL / AbCellera Biologics Inc. 27 May 2020 AbCellera Raises $105 Million Series B to Expand Therapeutic with an investor syndicate that includes Viking Global Investors, Peter Thiel, 23 Nov 2020 AbCellera, which raised over $100 million in VC funding from firms like DCVC, Viking Global and Founders Fund, also added Peter Thiel to its 31 Dec 2020 Stock Holdings page. Viking Global Investors. Period: Q4 2020 ABCL - AbCellera Biologics Inc. 2.13, 19,283,744, Buy, $40.24, $775,978,000. 20 Nov 2020 AbCellera Biologics is a privately-held company. Aside from Peter Thiel, the other investors include Founders Fund, Eli Lilly and Company, Viking 19 Feb 2021 Abalone Bio; AbbVie; AbCellera; Abstract Ventures; Accelerate Long Verge Genomics; VeriSIM; Versant Ventures; Viking Global Investors A list of the top 50 holdings of Viking Global Investors LP, derived from Viking Global ABCELLERA BIOLOGICS INC, 19,283,744, +19,283,744, $775,978.
2020年5月27日 本次融资由OrbiMed 和目前的投资人DCVC Bio 牵头，投资财团包括Viking Global Investors 、 Peter Thiel 、 Founders Fund 、礼来（Eli Lilly）
2021-03-13 Shares in Abcellera Biologics Inc are currently priced at $28.35. At that level they are trading at 84.83% discount to the analyst consensus target price of 0.00. Analysts covering Abcellera Biologics Inc currently have a consensus Earnings Per Share (EPS) forecast of 1.344 for the next financial year.
Find the latest AbCellera Biologics Inc. (ABCL) stock discussions in Yahoo of institutional investors in the last quarter, including Viking Global Investors LP,
The stock had previously closed at $26.58. A number of equities research analysts recently issued reports on ABCL […] 1 dag sedan · AbCellera Biologics Inc. (NASDAQ: ABCL) is -29.55% lower on its value in year-to-date trading and has touched a low of $23.20 and a high of $71.91 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. When you think about Vikings, you probably don't think about skiing, good hygiene and gender equality. Instead, you probably imagine long beards, lots of physical brutality and barrels of alcohol.
Andreas Halvorsen's Viking Global Buys UnitedHealth, Ups Stake in Visa. Feb.
16 Dec 2020 Vancouver biotech company AbCellera Biologics has officially that included Viking Global Investors, Peter Thiel of Founders Fund, the
8 Dec 2020 Viking Global Investors and Falcon Edge Capital stand to benefit from the initial public offering of AbCellera Biologics, the company that with
This page shows recent SEC filings related to AbCellera Biologics Inc 2021-02 -13, SC 13G/A, ABCL / AbCellera Biologics Inc. / VIKING GLOBAL INVESTORS
Stockopedia rates Abcellera Biologics Inc as a Speculative Falling Star . 3 brokers rate it as a 'Buy'.
Viking Global(Andreas Halvorsen)added new positions in General Electric (GE), AbCellera Biologics (ABCL), The Walt Disney (DIS) and UnitedHealth (UNH).Notable increases: Boston AbCellera, based in Vancouver, British Columbia, closed a Series B financing worth $105 million. The round was led by OrbiMed and DCVC Bio, with an investor syndicate that includes Viking Global Investors, Peter Thiel, Founders Fund, Eli Lilly and Company, University of Minnesota and Presight Capital.
AbCellera Biologics investors include DCVC Bio, Viking Global Investors, OrbiMed, Baker Brothers, Peter Thiel/Founders Fund, Eli Lilly and Company, Harvard Management Private Equity Corporation, and the University of Minnesota. Carl Hansen, Director and CEO of AbCellera Biologics Inc., in Vancouver, on Dec. 2, 2020. DARRYL DYCK/The Globe and Mail After Carl Hansen co-founded AbCellera Biologics Ltd. in 2012, people
AbCellera said it’s entitled to receive a specified percentage of proceeds that Lilly receives from these sales. while DCVC Bio LP has a 12.4% stake and Viking Global Investors and its
Viking Global Investors, L.P. is the top institutional holder at ABCL for having 19.28 Million shares of worth $775.98 Million.
gymnasiearbete mall engelska
information till dig som ar gift med ett barn
helena hedblom wikipedia
malmo hostel accommodation
AbCellera, based in Vancouver, British Columbia, closed a Series B financing worth $105 million. The round was led by OrbiMed and DCVC Bio, with an investor syndicate that includes Viking Global Investors, Peter Thiel, Founders Fund, Eli Lilly and Company, University of Minnesota and Presight Capital.
Data Collective is the second largest shareholder owning 11% of common stock, and Viking Global Investors LP holds about 7.2% of the company stock. We did some more digging and found that 7 of the top shareholders account for roughly 50% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat. Viking Global(Andreas Halvorsen)added new positions in General Electric (GE), AbCellera Biologics (ABCL), The Walt Disney (DIS) and UnitedHealth (UNH).Notable increases: Boston AbCellera, based in Vancouver, British Columbia, closed a Series B financing worth $105 million.
Willys medarbetare e-learning
epost svenska kyrkan
- Jägare skrämmer björn
- Klockljungsvägen sölvesborg
- Pay and pay for
- Rouge restaurant miami
- Niiice audiotree
- Kajor aneby kommun
Full-stack, AI-powered therapeutic antibody drug discovery platform
Canadian biotech firm AbCellera Biologics has raised $105m in a Series B funding round to advance its artificial intelligence (AI)-powered antibody drug discovery platform. OrbiMed and DCVC Bio led the financing round, with participation from Viking Global Investors, Peter Thiel, Founders Fund, Eli Lilly, University of Minnesota and Presight Capital. AbCellera Biologics has filed to raise $357 million in an IPO. The firm provides an antibody research platform to biopharmaceutical firms worldwide. AbCellera’s IPO date hasn't been set. The offering could happen as soon as next month.